Dr. Reddy's Laboratories launches of Penicillamine Capsules in the U.S. Market

▴ Dr. Reddy's Laboratories launches of Penicillamine Capsules in the U.S. Market
Dr Reddy's is on expansion mode

DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.Dr. Reddy’s Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.

Recently the company also announced the entry into the hospital nutrition segment with the launch of its nutrition drink, ‘Celevida Maxx’ in India. It is a unique addition to the Dr. Reddy’s nutrition portfolio and is designed to help manage the nutritional needs of Cancer, Critical Care and Chronic Obstructive Pulmonary Disease (COPD) patients in India.

M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories said, “We are pleased to foray into the hospital nutrition segment in India. With Celevida Maxx, we look forward to strengthening our presence in the nutrition segment and continue making a
positive impact on patients’ lives.”

Dr. Reddy’s Celevida Maxx contains a unique triple action formula of high protein, high omega 3 fatty acids to help tackle the problem of inflammation and Astaxanthin, which is clinically proven to support immunity. A single serving of Celevida Maxx has been designed keeping patient compliance in mind. It offers high protein in a single serve of 33 gms, with medium chain triglycerides (MCT) that get easily absorbed in the body and readily provide energy. Malnourished patients need ready source of energy that can be easily absorbed with high protein thereby helping stabilize the rapid weight loss that is seen in conditions like cancer.
Celevida Maxx contains vegetarian ingredients, no added sugar and comes in two flavors, Orange and Strawberry.

Cancer is the second most common cause of death in India and the estimated number of people living with the disease is around 2.25 million. It is noted that, the prevalence of malnutrition in Cancer patients is as high as 80% and up to 78% in critical care patients. As a result, patients suffer further complications like fatigue, poor response to treatment and increased hospital stay which in turn further decreases the nutritional status of the patients. The recent guidelines on Medical Nutrition Therapy (MNT) highlights the importance of breaking the malnutrition cycle due to chronic diseases and its associated comorbidities. Thus, compliance with the right nutrition solution plays an equally important role to meet the
nutritional needs of patients.

In 2019, Dr. Reddy’s entered the nutritional market with Celevida, a clinically proven nutrition drink that
is designed for diabetes patients.

Tags : #DrReddys #Penicillamine #USAMarkets #LatestPharmaUpdateaug27

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024